Sorafenib (Tosylate)

Sorafenib (Tosylate)

• CAS Number: 475207-59-1
• UNSPSC Description: Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a ferroptosis activator[1].
• Target Antigen: Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR
• Type: Reference compound
• Related Pathways: Apoptosis;Autophagy;MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/Sorafenib-Tosylate.html
• Purity: 99.91
• Solubility: DMSO : ≥ 31 mg/mL
• Smiles: O=S(C1=CC=C(C=C1)C)(O)=O.O=C(NC2=CC=C(C(C(F)(F)F)=C2)Cl)NC3=CC=C(OC4=CC(C(NC)=O)=NC=C4)C=C3
• Molecular Weight: 637.03
• References & Citations: [1]Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109.|[2]Huynh H, et al. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med. 2009 Aug;13(8B):2673-83.|[3]El-Ashmawy NE, et al. Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor. Clin Exp Med. 2016 Apr 16.|[4]Zhu W, et al. Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt. Am J Cancer Res. 2017 Dec 1;7(12):2503-2514.Adv Sci (Weinh). 2022 Nov 29;e2203718.|Am J Cancer Res. 2017 Dec 1;7(12):2503-2514. |Am J Transl Res. 2021 Jul 15;13(7):7508-7523.|Autophagy. 2021 May 7;1-13.|Bone Res. 2024 Apr 10;12(1):24.|Fundam Clin Pharmacol. 2020 Oct 4. |Int J Biochem Cell Biol. 2020 Sep;126:105820.|Int J Mol Sci. 2022, 23(19), 11092.|J Enzyme Inhib Med Chem. 2020 Dec;35(1):344-353.|Math Biosci Eng. 2019 Jul 8;16(6):6319-6334.|NPJ Syst Biol Appl. 2019 Aug 16;5:29. |Oncotarget. 2017 Oct 6;8(52):90185-90196. |PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. |Saudi Pharm J. 2023 Jun 1.|ACS Appl Mater Interfaces. 2017 Apr 12;9(14):12195-12202.|ACS Chem Biol. 2016 Apr 15;11(4):992-1000.|ACS Chem Biol. 2017 Jan 20;12(1):282-290. |ACS Nano. 2023 Nov 15.|Acta Pharm Sin B. 2023 Mar 31.|Acta Pharm Sin B. 2023 Oct;13(10):4253-4272.|Acta Pharmacol Sin. 2021 Jan;42(1):108-114.|Adv Healthc Mater. 2023 Apr 14;e2203120.|Adv Sci (Weinh). 2021 Jan 29;8(6):2002831.|Adv Sci (Weinh). 2022 May;9(15):e2105894.|Adv Sci (Weinh). 2023 Jul 23;e2302640.|Adv Sci (Weinh). 2023 Jun 17;e2206798.|Adv Sci (Weinh). 2024 Jul 9:e2402327.|Advances in Parkinsons Disease. 2021, 10, 1-13.|Am J Digest Dis. 2015;2(2):95-99.|Am J Transl Res. 2020;12(3):825-836.|Am J Transl Res. 2023 Feb 28;15(2):896-913.|Biochem Bioph Res Co. 2020 Sep 3;529(4):1086-1093.|Biochem Biophys Res Commun. 13 January 2022.|Biochem Biophys Res Commun. 2023 Jun 10.|Biochem Pharmacol. 2023 Apr 18;115554.|Biochem Pharmacol. 2023 May 15;115593.|Biochem Pharmacol. 2019 Nov;169:113612. |Biology (Basel). 2023 Oct 16, 12(10), 1337.|Biomaterials. 16 September 2022.|Biomaterials. 17 March 2022.|Biomed Pharmacother. 2016 Dec 6;86:27-31.|Biomed Pharmacother. 2020 Jun;126:109862.|Biomed Pharmacother. September 2022, 113540.|Biomed Res Int. 2019 Nov 28;2019:2410845.|bioRxiv. 2021 Jan 25.|BMC Complement Med Ther. 2023 Jun 26;23(1):210.|BMC Cancer. 2019 Aug 1;19(1):760. |Br J Cancer. 2017 Sep 26;117(7):974-983.|Br J Pharmacol. 2021 Feb;178(3):636-653.|Braz J Med Biol Res. 2021 May 31;54(9):e10390.|Can J Gastroenterol Hepatol. 2022.|Cancer Cell Int. 2019 Aug 27;19:222.|Cancer Discov. 2019 Dec;9(12):1686-1695.|Cancer Discov. 2021 Oct;11(10):2544-2563.|Cancer Lett. 20 October 2021.|Cancer Lett. 2019 May 28;450:132-143.|Cancer Lett. 2021 Jul 30;S0304-3835(21)00382-7.|Cancers (Basel). 2023 Nov 3, 15(21), 5280.|Cancers. 2020 Jun 30;12(7):1737.|Cell Biol Toxicol. 2023 Mar 31.|Cell Commun Signal. 2024 Aug 7;22(1):391.|Cell Death Differ. 2021 Apr;28(4):1222-1236.|Cell Death Dis. 2021 Jul 9;12(7):691.|Cell Death Dis. 2022 Feb 4;13(2):118.|Cell Death Dis. 2023 Jan 12;14(1):22.|Cell Death Dis. 2024 Jan 18;15(1):66.|Cell Death Dis. 2024 Jun 5;15(6):395.|Cell Death Dis. 2019 Apr 15;10(5):331.|Cell Death Discov. 2022 Aug 17;8(1):365.|Cell Death Discov. 2023 Sep 30;9(1):362.|Cell Discov. 2022 May 3;8(1):40.|Cell Metab. 2021 Sep 8;S1550-4131(21)00375-2.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Cell Rep. 2023 Dec 12;42(12):113563.|Cell Rep. 2024 Nov 27;43(12):114996.|Cell Rep. 2024 Oct 24;43(11):114885.|Cell Signal. 2024 Jun 27:111278.|Chem Cent J. 2017 Jan 3;11:1.|Chemical Engineering and Applied Chemistry Institute of Biomaterials and Biomedical Engineering, University of Toronto. 2019 Aug.|Chemosphere. 2022 Sep 7;136354.|Chin J Nat Med. 2022 Mar;20(3):202-209.|Chin Med. 2024 Aug 24;19(1):113.|Clin Cancer Res. 2024 Jul 25.|Clin Med Insights Oncol. 2024 Oct 16:18:11795549241285387.|Clin Sci. 2021 Jul 20;CS20210571.|Clin Transl Med. 2023 Jun;13(6):e1300.|Commun Biol. 2024 Oct 8;7(1):1279.|Comput Biol Med. 2024 Feb, 169, 107975.|Dig Liver Dis. 2023 May 23;S1590-8658(23)00618-7.|Discov Oncol. 2023 May 27;14(1):83.|Diseases. 2023 Oct 23;11(4):147.|Drug Deliv. 2023 Dec;30(1):2174209.|Drug Des Devel Ther. 2024 Sep 12:18:4065-4088.|Endocr J. 2017 Nov 29;64(11):1115-1123.|Endocrinology. 2023 Sep 13;bqad135.|Environ Toxicol. 2021 Oct 18.|Eur J Med Chem. 2024 Mar 5:267:116209.|Eur J Pharmacol. 2021 Jun 1;174217.|Evid Based Complement Alternat Med. 15 Oct 2022.|Exp Cell Res. 2020 Aug 1;393(1):112054.|Exp Cell Res. 2021 Jul 29;112755.|Exp Cell Res. 2022 May 25;113223.|Exp Hematol Oncol. 2016 Jul 29;5:22. |Free Radic Biol Med. 2020 Nov 20;160:303-318.|Free Radic Biol Med. 2021 Feb 1;163:141-152.|Front Biosci (Landmark Ed). 2024 Jan 19, 29(1), 3.|Front Oncol. 2021 Jul 13;11:704042.|Front Oncol. 2022 Jul 8;12:939605.|Front Pharmacol. 2022 Jul 11;13:930958.|Front Pharmacol. 2024 Apr 5.|Genes Dis. 2023 Sep 16, 101114.|Gut Microbes. 2024 Jan-Dec;16(1):2410474.|Heliyon. 2024 Jan 13, e24461.|Heliyon. 2024 May 31.|Hepatol Commun. 2024 Mar 29;8(4):e0405.|Immunology. 2023 Apr 17.|Int Immunopharmacol. 2024 Sep 30;143(Pt 1):113226.|Int J Biol Sci. 2018 Apr 25;14(5):577-585.|Int J Clin Exp Pathol. 2015 Apr 1;8(4):3871-81.|Int J Clin Exp Pathol. 2017;10(3):3033-3042.|Int J Med Sci. 2021 Jan 29;18(6):1456-1464.|Int J Mol Sci. 2023 Dec 23, 25(1), 269.|Integr Biol (Camb). 2018 Oct 15;10(10):646-657.|iScience. 2023 May 29, 106994.|J Cancer. 2021 Jan 1;12(2):343-357.|J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 1;1061-1062:220-224.|J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Mar 26:1237:124100.|J Ethnopharmacol. 2021 Aug 4;280:114480.|J Exp Clin Cancer Res. 2022 Mar 30;41(1):116.|J Exp Clin Cancer Res. 2023 Jan 6;42(1):6.|J Exp Clin Cancer Res. 2018 Nov 29;37(1):295.|J Extracell Vesicles. 2024 Jul;13(7):e12468.|J Hepatocell Carcinoma. 2023 Apr 11;10:611-629.|J Immunother Cancer. 2022 Aug;10(8):e004006.|J Med Chem. 2019 Nov 14;62(21):9593-9599. |J Mol Med (Berl). 2022 Feb 5.|J Pharmacol Exp Ther. 2017 Aug;362(2):219-229. |J Transl Med. 2022 Jun 6;20(1):255.|J Transl Med. 2023 Jan 9;21(1):9.|J Transl Med. 2024 Aug 28;22(1):792.|Journal of Pharmaceutical Research International. 33(47B): 274-279, 2021.|Kaohsiung J Med Sci. 16 November 2021.|Lab Chip. 2018 Nov 6;18(22):3379-3392.|Med Oncol. 2022 Sep 29;39(12):221.|Mol Cancer Ther. 2020 May;19(5):1197-1209.|Mol Carcinog. 2023 May 22.|Mol Cell Probes. 2022 Nov 25;101877.|Mol Cell. 2023 Dec 7;83(23):4334-4351.e7.|Mol Oncol. 19 August 2022.|Molecules. 2018 Mar 23;23(4). pii: E736.|Nat Cancer. 2024 May 30.|Nat Commun. 2022 Mar 18;13(1):1478.|Nat Commun. 2024 Sep 10;15(1):7923.|Neuropharmacology. 2019 Jan 30;148:347-357.|Oncogene. 2021 Jul 10.|Oncogene. 2022 Feb 10.|Oncol Rep. 2017 Jan;37(1):273-280. |Oncol Rep. 2018 Sep;40(3):1525-1532. |Oncol Rep. 2020 Dec 9.|Oncotarget. 2017 May 2;8(18):29771-29784.|Pakistan J Zool. 2021 May.|Patent. US20180263995A1.|Patent. US20220305013A1.|Personalized Medicine Universe. 2019 May. |Pharmacol Res. 2021 Dec 29;106050.|Pharmacol Res. 2022 Jun;180:106244.|Phytochemistry. 2021 Jun 1;189:112816.|Phytomedicine. 2023 Nov 25, 155225.|Phytomedicine. 8 September 2021, 153740.|Prostate. 2018 Apr;78(5):343-352.|Redox Biol. 2022: 102564.|Redox Biol. 2024 Mar 28:72:103131.|Res Sq. 2024 Sep 16.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2022 Jul.|Research Square Preprint. 2022 May.|Research Square Preprint. 2023 Mar 29.|Research Square Preprint. 2023 Nov 11.|Research Square Print. 2023 Feb 20.|Research Square Print. October 3rd, 2022.|RSC Adv. 2018 8:6425-6435.|Sci Rep. 2017 Sep 8;7(1):11006. |Sci Rep. 2022 Apr 21;12(1):6120.|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.|Sens Actuators B Chem. 2024 Nov 1.|Signal Transduct Target Ther. 2023 Sep 14;8(1):348.|SSRN. 2023 Apr 24.|SSRN. 2023 Jan 27.|SSRN. 2024 Oct 16.|Stem Cell Res Ther. 2023 Apr 1;14(1):58.|Theranostics. 2020 Aug 21;10(23):10498-10512. |Toxicol In Vitro. 2021 Jul 20;76:105226.|Toxicology. 2023 Mar 2;153475.|Virol Sin. 2023 Jul 3;S1995-820X(23)00079-2.|World J Gastroenterol. 2021 Jul 28;27(28):4667-4686.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Launched